comprehensive -WSS

comprehensive

author：fashion 2025-09-27 13:10:02 - browse：6

Photograph of Glaxo Smith Kline headquarters in London for a story on multiple myeloma cancer treatment ahead of the 2024 ASCO conference — JUSTIN TALLIS/AFP via Getty Images

LONDON — The resurrection of a GSK blood cancer drug — which the company withdrew from the U.S. market not even two years ago after it failed a key study — is taking its next step forward.

At the annual American Society of Clinical Oncology conference in Chicago, researchers on Sunday are presenting trial data showing that the drug, called Blenrep, outperformed a standard therapeutic approach when combined with another medicine in patients with multiple myeloma. It’s the second positive study for Blenrep in myeloma in recent months, and next up could be a return to regulatory agencies to get the drug re-approved.

In an interview, Hesham Abdullah, GSK’s oncology research leader, said the company planned to submit Blenrep to regulators by the end of the year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Custom gene therapy hints at new path for rare disease treatments

leisure time

WSS

After sickle

Listen: Wegovy in the brain & pivotal Alzheimer's data

FDA approves RSV monoclonal antibody for infants, toddlers

Supreme Court wrestles with OxyContin maker's bankruptcy deal

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Startup Neumora takes a novel depression drug to Phase 3

leisure time

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

In age of alternative facts, a scholarly course on calling out crap

At Orexo, a ‘turning point’ for everything but digital health

In Memoriam: Notable people who died in 2023

Google and Epic fight stronger regulation of AI in health care

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Spinal cord stimulation reduces pain in amputees, study finds

Jerome Adams on the need for new antivirals for Covid

Biden tests positive for Covid

Bright Health sells Medicare Advantage business to Molina

At Orexo, a ‘turning point’ for everything but digital health

entertainment

Chemotherapy shortages won’t get better under Biden’s latest plan

What PEPFAR has meant on the ground in Ukraine

Radiology is caught between AI's potential and concern for patients

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Sanders adds drug shortage policies to pandemic preparedness bill

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

hotspot

leisure time

focus

leisure time